Activation of mouse and human peroxisome proliferator-activated receptors (α, β/δ, γ) by perfluorooctanoic acid and perfluorooctane sulfonate

Toxicological Sciences

Volumn 95, Issue 1, 2007, Pages 108-117

  Takacs, Margy L ^a   Abbott, Barbara D ^a,b  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Cos 1 cells; PFOA; PFOS; PPAR; Transient transfection assay

Indexed keywords

2CHLORO 5 NITROBENZANILIDE; 3[3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; DIMETHYL SULFOXIDE; LUCIFERASE; PERFLUOROOCTANE; PERFLUOROOCTANOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; WATER;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL STRAIN COS1; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYOTOXICITY; FETOTOXICITY; GENETIC TRANSFECTION; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PLASMID; PREDICTION; RECEPTOR UPREGULATION; TOXICITY TESTING; TOXICOLOGY;

ALKANESULFONIC ACIDS; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; FLUOROCARBONS; GENES, REPORTER; HUMANS; LUCIFERASES; MICE; OCTANOIC ACIDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PPAR-BETA; SPECIES SPECIFICITY; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

BOS TAURUS;

EID: 33845609258     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfl135     Document Type: Article

References (57)

1. Asami-Miyagishi, R., Iseki, S., Usui, M., Uchida, K., Kubo, H., and Morita, I. (2004). Expression and function of PPARgamma in rat placental development. Biochem. Biophys. Res. Commun. 315, 497-501.
2. Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., and Vidal, H. (1997). Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319-1327.
3. Berger, J., Leibowitz, M.D., Doebber, T.W., Elbrecht, A., Zhang, B., Zhou, G., Biswas, C., Cullinan, C.A., Hayes, N.S., Li, Y., et al. (1999). Novel peroxisome-proliferator-activated receptor (PPAR) gamma and PPAR delta ligand produce distinct biological effects. J. Biol. Chem. 274, 6718-6725.
4. Berry, E., Eykholt, R., Helliwell, R., Gilmour, R., Mitchell, M., and Marvin, K. (2003). Perioxisome proliferator-activated receptor isoform expression changes in human gestational tissues with labor at term. Mol. Pharmacol. 64, 1586-1590.
5. Bility, M. T., Thompson, J. T., McKee, R. H., David, R. M., Butala, J. H., Vanden Heuvel, J. P., and Peters, J. M. (2004). Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol. Sci. 82, 170-182.
6. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354-366.
7. Braissant, O., and Wahli, W. (1998). Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139, 2748-2754.
8. Burgess, H., Daugherty, L., Thatcher, T., Lakatos, H., Ray, D., Redonnet, M., Phipps, R., and Sime, P. (2005). PPARγ agonist inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: Implication for therapy of lung fibrosis. Am J. Physiol. Lung Cell Mol. Physiol. 288, L1146-L1153.
9. Butenhoff, J. L., Kennedy, G. L., Jr, Frame, S. R., O'Connor, J. C., and York, R. G. (2004). The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat. Toxicology 196, 95-116.
10. Case, M. T., York, R. G., and Christian, M. S. (2001). Rat and rabbit oral developmental toxicology studies with two perfluorinated compounds. Int. J. Toxicol. 20, 101-109.
11. Christian, M. S., Hoberman, A. M., and York, R. G. (1999). Combined oral (gavage) fertility, developmental and perinatal/postnatal reproduction toxicity study of PFOS in rats. Argus Research Laboratories, Inc., Horsham, PA.
12. Ding, N. Z., Ma, X. H., Diao, H. L., Xu, L. B., and Yang, Z. M. (2003a). Differential expression of peroxisome proliferator-activated receptor delta at implantation sites and in decidual cells of rat uterus. Reproduction 125, 817-825.
13. Ding, N. Z., Teng, C. B., Ma, H., Ni, H., Ma, X. H., Xu, L. B., and Yang, Z. M. (2003b). Peroxisome proliferator-activated receptor delta expression and regulation in mouse uterus during embryo implantation and decidualization. Mol. Reprod. Dev. 66, 218-224.
14. Dunn-Albanese, L. R., Ackerman, W. E. 4th, Xie, Y., Iams, J. D., and Kniss, D. A. (2004). Reciprocal expression of peroxisome proliferator-activated receptor-gamma and cyclooxygenase-2 in human term parturition. Am. J. Obstet. Gynecol. 190, 809-816.
15. 1/2) of elimination of perfluorooctanoate (PFOA) from human serum. Toxicologist 84, 253.
16. Escher, P., and Wahli, W. (2000). Peroxisome proliferator-activated receptors: Insight into multiple cellular functions. Mutat. Res. 448, 121-138.
17. Giesy, J., and Kannan, K. (2001). Global distribution of perfluorooctane sulfonate in wildlife. Environ. Sci. Technol. 35, 1339-1342.
18. Giesy, J., and Kannan, K. (2002). Perfluorochemical surfactants in the environment. Environ. Sci. Technol. 36, 146A-152A.
19. Gortner, E. (1980). Oral teratology study of fc-95 in rats. Riker Laboratories, Inc., St Paul, MN.
20. Grasty, R. C., Grey, B. E., Lau, C. S., and Rogers, J. M. (2003). Prenatal window of susceptibility to perfluorooctane sulfonate-induced neonatal mortality in the Sprague-Dawley rat. Birth Defects Res. B Dev. Reprod. Toxicol. 68, 465-471.
21. Hansen, K., Clemen, L., Ellefson, M., and Johnson, H. (2001). Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ. Sci. Technol. 35, 766-770.
22. Hihi, A. K., Michalik, L., and Wahli, W. (2002). PPARs: Transcriptional effectors of fatty acids and their derivatives. Cell Mol. Life Sci. 59, 790-798.
23. Intrasuksri, U., Rangwala, S., O'Brien, M., Noonan, D., and Feller, D. (1998). Mechanisms of peroxisome proliferation by perfluorooctanoic acid and endogenous fatty acids. Gen. Pharmacol. 31, 187-197.
24. Kannan, K., Franson, J., Bowerman, W., Hansen, K., Jones, P., and Giesy, J. (2001a). Perfluorooctane sulfonate in fish-eating water birds including bald eagles and albatrosses. Environ. Sci. Technol. 35, 3065-3070.
25. Kannan, K., Koistinen, J., Beckmen, K., Evans, T., Gorzelany, J., Hansen, K., Jones, P., Helle, E., Nyman, M., and Giesy, J. (2001b). Accumulation of perfluorooctane sulfonate in marine mammals. Environ. Sci. Technol. 35, 1593-1598.
26. Kehrer, J., Biswal, S., Eunhye, L., Thuillier, P., Datta, K., Fischer, S., and Vanden Heuvel, J. (2001). Inhibition of peroxisome-proliferator-activated receptor (PPAR)a by MK886. Biochem. J. 356, 899-906.
27. Keller, J. M., Collet, P., Bianchi, A., Huin, C., Bouillaud-Kremarik, P., Becuwe, P., Schohn, H., Domenjoud, L., and Dauca, M. (2000). Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease. Int. J. Dev. Biol. 44, 429-442.
28. Keller, H., and Wahli, W. (1997). Principles of Medical Biology, Molecular and Cellular Endocrinology. JAI Press, Greenwich, CT.
29. Kennedy, G., Butenhoff, J., Olsen, G., O'Connor, J., Seacat, A., Perkins, R., Biegel, L., Murphy, S., and Farrar, D. (2004). The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 34, 351-384.
30. Kim, D., Bility, M., Billin, A., Wilson, T., Gonzalez, F., and Peters, J. (2006). PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 13, 53-60.
31. Komar, C., and Curry, T. J. (2002). Localization and expression of messenger RNAs for the peroxisome proliferator-activated receptors in ovarian tissue from naturally cycling and pseudopregnant rats. Biol. Reprod. 66, 1531-1539.
32. Lau, C., Butenhoff, J. L., and Rogers, J. M. (2004). The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol. Appl. Pharmacol. 198, 231-241.
33. Lau, C., Thibodeaux, J. R., Hanson, R. G., Narotsky, M. G., Rogers, J. M., Lindstrom, A. B., and Strynar, M. J. (2006). Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol. Sci. 90, 510-518.
34. Lau, C., Thibodeaux, J. R., Hanson, R. G., Rogers, J. M., Grey, B. E., Stanton, M. E., Butenhoff, J. L., and Stevenson, L. A. (2003). Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: Postnatal evaluation. Toxicol. Sci. 74, 382-392.
35. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953-12956.
36. Lim, H., Gupta, R., Ma, W., Paria, B., Moller, D., Morrow, J., DuBois, R., Trzaskos, J., and Dey, S. (1999). Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ. Genes Dev. 13, 1561-1574.
37. Maloney, E. K., and Waxman, D. J. (1999). Trans-activation of PPARalpha and PPARgamma by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 161, 209-218.
38. Mangelsdorf, D. Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995). The nuclear receptor superfamily: The second decade. Cell 83, 835-839.
39. Mukherjee, R., Jow, L., Croston, G. E., and Paterniti, J. R., Jr. (1997). Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. 272, 8071-8076.
40. Olsen, G. W., Huang, H. Y., Helzlsouer, K. J., Hansen, K. J., Butenhoff, J. L., and Mandel, J. H. (2005). Historical comparison of perfluorooctanesulfonate, perfluorooctanoate, and other fluorochemicals in human blood. Environ. Health Perspect. 113, 539-545.
41. Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., and Peters, J. M. (2006). The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol. Sci. 90, 269-295.
42. Peters, J., Cheung, C., and Gonzalez, F. (2005). Peroxisome proliferator-activated receptor-alpha and liver cancer: Where do we stand?. J. Mol. Med. 83, 774-785.
43. Renner, R. (2001). Growing concern over perfluorinated chemicals. Environ. Sci. Technol. 35, 154A-160A.
44. Rodie, V., Young, A., Jordan, F., Sattar, N., Greer, I., and Freeman, D. (2005). Human placental peroxisome proliferator-activated receptor delta and gamma expression in healthy pregnancy and in preeclampsia and intrauterine growth restriction. J. Soc. Genecol. Invest. 12, 320-329.
45. Shipley, J. M., Hurst, C. H., Tanaka, S. S., DeRoos, F. L., Butenhoff, J. L., Seacat, A. M., and Waxman, D. J. (2004). Trans-activation of PPARalpha and induction of PPARalpha target genes by perfluorooctane-based chemicals. Toxicol. Sci. 80, 151-160.
46. Starkov, A., and Wallace, K. (2002). Structural determinants of fluorochemicals-induced mitochondrial dysfunction. Toxicol. Sci. 66, 244-252.
47. Sugden, M., and Holness, M. (2004). Potential role of peroxisome proliferator-activated receptor-alpha in the modulation of glucose-stimulated insulin secretion. Diabetes 53, S71-S81.
48. Tarrade, A., Schoonjans, K., Guibourdenche, J., Bidart, J. M., Vidaud, M., Auwerx, J., Rochette-Egly, C., and Evain-Brion, D. (2001). PPAR gamma/RXR alpha heterodimers are involved in human CG beta synthesis and human trophoblast differentiation. Endocrinology 142, 4504-4514.
49. Taves, D. (1968). Evidence that there are two forms of fluoride in human serum. Nature 217, 1050-1051.
50. Teruel, T., Clapham, J. C., and Smith, S. A. (1999). PPARalpha activation by Wy 14643 induces transactivation of the rat UCP-1 promoter without increasing UCP-1 mRNA levels and attenuates PPARgamma-mediated increases in UCP-1 mRNA levels induced by rosiglitazone in fetal rat brown adipocytes. Biochem. Biophys. Res. Commun. 264, 311-315.
51. Thibodeaux, J. R., Hanson, R. G., Rogers, J. M., Grey, B. E., Barbee, B. D., Richards, J. H., Butenhoff, J. L., Stevenson, L. A., and Lau, C. (2003). Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: Maternal and prenatal evaluations. Toxicol. Sci. 74, 369-381.
52. U.S. Environmental Protection Agency. (2005). Draft Risk Assessment of Human Health Effects Associated with Exposure to Perfluorooctanoic Acid and its Salts, January, 2005. US EPA, Madison, WI. Available at: Http:// www.epa.gov/opptintro/pfoa/pubs/pfoarisk.htm.
53. Vanden Heuvel, J., Thompson, J., Frame, S., and Gillies, P. (2006). Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: A comparison of human, mouse, and rat PPARα, β, γ, LXRβ and RXRα. Toxicol. Sci. 92, 476-489.
54. Vidal-Puig, A., Considine, R., Jimenez-Linan, M., Werman, A., Pories, W., Caro, J., and Flier, J. (1997). Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids J. Clin. Invest. 99, 2416-2422.
55. Wahli, W. (2002). Peroxisome proliferator-activated receptors (PPARs): From metabolic control to epidermal wound healing. Swiss Med. Wkly. 132, 83-91.
56. Wetzel, L. (1983). Rat teratology study, T-3351. Final report. Hazelton Laboratories America, Inc., Madison, WI.
57. Yang, Q., Abedi-Valugerdi, M., Xie, Y., Zhao, X. Y., Moller, G., Nelson, B., and DePierre, J. (2002). Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2, 389-397.